NextEra Energy stock rises after Google power deal report
Recursion Pharmaceuticals NASDAQ:RXRX Chief Executive Officer Christopher Gibson sold 100,000 shares of Class A Common Stock on October 23, 2025, at a price of $5.70, totaling $570,000. The sale occurred as the stock trades at $6.03, with the company currently valued at $2.6 billion. According to InvestingPro analysis, Recursion maintains strong liquidity with a current ratio of 3.58, though the company faces profitability challenges.
On the same day, Gibson also converted 100,000 shares of Class B Common Stock into Class A Common Stock. The price for this transaction was $0. With the company’s next earnings report due on November 5, 2025, InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report to better understand the company’s financial position.
Following these transactions, Gibson directly owns 954,229 shares of Class A Common Stock. He also indirectly owns derivative securities through various entities, including LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust. These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025.
In other recent news, Recursion Pharmaceuticals reported its second-quarter 2025 earnings, highlighting a significant revenue beat. The company achieved revenue of $19.22 million, surpassing the forecasted $15.37 million by 25.05%. However, the earnings per share (EPS) did not meet expectations, posting an actual EPS of -$0.41 compared to the anticipated -$0.35, resulting in a 17.14% negative surprise. Despite the EPS shortfall, the strong revenue performance indicates positive momentum for the company. These recent developments reflect investor optimism, even amid the mixed earnings results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.